Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 7/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | LYN | P07948 | 3/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | DDX3X | O00571 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL29351601 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29355523 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2236091 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL15201213 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2929858 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3138052 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1462774 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL529425 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1977949 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL16431247 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 124472 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146232-A1 | METHODS FOR PROMOTING HOMING AND ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144750-A1 | Dosing Regimens for Treatment of Glioblastoma | SIGNPATH PHARMA INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137650-A1 | MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) | 11949098 CANADA INC (CA) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-1259242-A2 | USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY | Novartis AG (CH) | 2002-11-27 | — | — | EP | claimed |
| WO-2002092091-A1 | COMBINATION COMPRISING N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2PYRIMIDINE-AMINE AND A CHEMOTHERAPEUTIC AGENT | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | claimed |
| WO-2002080708-A2 | A SMOKER'S REQUISITE | ENSLIN GEORGE FREDERICK (ZA) | 2002-10-17 | — | — | WO | claimed |
| WO-2002080925-A1 | USE OF N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVEA AGAINST MAST CELL-BASED DISEASES LIKE ALLERGIC DISORDERS | NOVARTIS AG (CH) | 2002-10-17 | — | — | WO | claimed |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TAIJI BIOMEDICAL, INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002067941-A2 | COMBINATION COMPRISING A SIGNAL TRANSDUCTION INHIBITOR AND AN EPOTHILONE DERIVATIVE | NOVARTIS AG (CH) | 2002-09-06 | — | — | WO | claimed |
| WO-2001064200-A2 | USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY | NOVARTIS AG (CH) | 2001-09-07 | — | — | WO | claimed |
| EP-0564409-B1 | Pyrimidin derivatives and process for their preparation | NOVARTIS AG (CH) | 2000-01-19 | — | — | EP | claimed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | claimed |
| EP-0564409-A1 | Pyrimidin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-10-06 | — | — | EP | claimed |